LAP3 (leucine aminopeptidase 3) has been reported to play a vital role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is a known risk factor for T2DM [50] and is associated with cardiovascular and cerebrovascular diseases [51]. Here, LAP3 is linked to cerebrovascular disorder.